Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 18:4:e144-e150.
doi: 10.5114/amsad.2019.86752. eCollection 2019.

Can metformin stabilize PCSK9 level in stable coronary artery disease patients treated with statins?

Aleksandr B Shek  1 , Rano B Alieva  1 , Ravshanbek D Kurbanov  1 , Shavkat U Hoshimov  1 , Ulugbek I Nizamov  1 , Adolat V Ziyaeva  1
Affiliations

Can metformin stabilize PCSK9 level in stable coronary artery disease patients treated with statins?

Aleksandr B Shek et al. Arch Med Sci Atheroscler Dis. .

Abstract

Introduction: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as an important marker of cardiovascular risk and a new target for therapeutic interventions. We aimed to study the influence of metformin on the level of circulating PCSK9 in patients with stable coronary artery disease (SCAD) and type 2 diabetes (T2DM) or metabolic syndrome (MetS), receiving moderate doses of statins used in routine clinical practice.

Material and methods: The study included 80 patients with T2DM or MetS receiving rosuvastatin for at least three months prior the study. MetS was diagnosed based on the Global Consensus Definition of the International Diabetes Federation (IDF). Serum level of PCSK9 was measured with an ELISA kit.

Results: Patients with T2DM or MetS, who took part in the research, were divided into 2 groups - those who received metformin prior the main study (21 patients - 1st group) and patients who did not (59 patients - 2nd group). Addition of metformin to the 3-month statin therapy of the 2nd group patients, divided into subgroup A (n = 27) with the addition of metformin and subgroup B (n = 29) without one, did not significantly affect the level of lipids. However, the level of circulating PCSK9 in subgroup A patients decreased, compared to subgroup B (p < 0.01). At the same time, ongoing metformin and rosuvastatin therapy in the 1st group patients was not accompanied by a further decrease of the PCSK9 level.

Conclusions: The addition of metformin to ongoing rosuvastatin therapy did not significantly affect serum lipid levels, but stabilized the level of circulating PCSK9, compared with the group without metformin treatment.

Keywords: metabolic syndrome; metformin; proprotein convertase subtilisin/kexin type 9; rosuvastatin; type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J. 2016;37:2999–3058. - PubMed
    1. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78. - PubMed
    1. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356:2388–98. - PubMed
    1. Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114:1022–36. - PubMed
    1. Waters DD, Brotons C, Chiang CW, et al. Lipid Treatment Assessment Project 2 Investigators; Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120:28–34. - PubMed

LinkOut - more resources